drugset
drugset / Trial / NCT01813305

CSTC1 for Diabetic Foot Ulcers Phase II Study

NCT01813305 ↗

Phase 2 Completed 124 enrolled Charsire Biotechnology Corp. ASKLEP Inc. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of CSTC1 in patient with diabetic foot ulcers.

Timeline

Start
2014-07-09
Primary completion
2020-01-07
Completion
2020-01-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator CSTC1 Unknown — Topical

Indications

diabetes mellitus ulcer of lower limbs